These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
392 related items for PubMed ID: 25224616
1. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. Mack N, Evens EM, Tolley EE, Brelsford K, Mackenzie C, Milford C, Smit JA, Kimani J. J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616 [Abstract] [Full Text] [Related]
2. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment. Quaife M, Eakle R, Cabrera M, Vickerman P, Tsepe M, Cianci F, Delany-Moretlwe S, Terris-Prestholt F. BMJ Open; 2016 Jun 27; 6(6):e010682. PubMed ID: 27354071 [Abstract] [Full Text] [Related]
3. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, VOICE-C Study Team. J Int AIDS Soc; 2014 Jun 27; 17(3 Suppl 2):19146. PubMed ID: 25224610 [Abstract] [Full Text] [Related]
8. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C. J Acquir Immune Defic Syndr; 2019 Apr 01; 80(4):394-403. PubMed ID: 30633040 [Abstract] [Full Text] [Related]
9. Women and ARV-based HIV prevention - challenges and opportunities. Geary CW, Bukusi EA. J Int AIDS Soc; 2014 Apr 01; 17(3 Suppl 2):19356. PubMed ID: 25224621 [Abstract] [Full Text] [Related]
11. Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. Atujuna M, Newman PA, Wallace M, Eluhu M, Rubincam C, Brown B, Bekker LG. PLoS One; 2018 Apr 01; 13(2):e0191251. PubMed ID: 29420549 [Abstract] [Full Text] [Related]
13. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa. Grant H, Gomez GB, Kripke K, Barnabas RV, Watts C, Medley GF, Mukandavire Z. Sex Transm Dis; 2020 Nov 01; 47(11):767-777. PubMed ID: 33044426 [Abstract] [Full Text] [Related]
16. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa. Fynn L, Gill K, Wallace M, Atujuna M, Duyver M, Ngcobo P, Spiegel H, Rinehart A, Hosek S, Bekker LG. BMC Public Health; 2023 Nov 02; 23(1):2143. PubMed ID: 37919697 [Abstract] [Full Text] [Related]
18. Experiences of oral pre-exposure prophylaxis use among heterosexual men accessing sexual and reproductive health services in South Africa: a qualitative study. Cholo FA, Dada S, Martin CE, Mullick S. J Int AIDS Soc; 2024 May 02; 27(5):e26249. PubMed ID: 38695102 [Abstract] [Full Text] [Related]
19. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM. AIDS Behav; 2017 May 02; 21(5):1361-1375. PubMed ID: 27317411 [Abstract] [Full Text] [Related]